Elecsys® Alzheimer’s Disease Testing Sites

 

FDA-cleared biomarkers to support early diagnosis of Alzheimer’s
Alzheimer's Disease doesn't wait. Neither should a diagnosis.

Here are the laboratories offering the Elecsys® Alzheimer’s tests for send-out orders:

ARUP Laboratories

500 Chipeta Way
Salt Lake City, UT 84108
Test(s) Offered: pTau181/AB42 CSF; tTau/AB42 CSF
Test Order ID: 3017653
https://ltd.aruplab.com/Tests/Pub/3017653

Clinical Pathology Laboratories

9200 Wall St.
Austin, TX 78754
Test(s) Offered: pTau181/AB42 CSF; tTau/AB42 CSF
Test Order ID: 3015
https://www.cpllabs.com/clinicians/client-communications/ad-eval/

Labcorp

531 S. Spring St.
Burlington, NC 27215
Test(s) Offered: pTau181/AB42 CSF; tTau/AB42 CSF
Test Order ID: 484415
https://www.labcorp.com/tests/484415/alzheimer-s-disease-evaluation-profile-csf

Mayo Clinic Laboratories

3050 Superior Drive NW
Rochester, MN 55905
Test(s) Offered: pTau181/AB42 CSF
Test Order ID: ADEVL
https://www.mayocliniclabs.com/test-catalog/overview/607273

TrilliumBiO

9808 Medical Center Drive, Suite 330
Rockville, MD 20850
Test(s) Offered: pTau181/AB42 CSF; tTau/AB42 CSF
Test Order ID: ALZT
https://trilliumbio.com/alzheimers/

Have a lab running Elecsys® Alzheimer’s assays?
 

Fill out this form to have your lab featured here.

 

Here is how your information will look when featured: 

Example Lab

123 Maple Street
City, State, Zip Code
Test(s) Offered: pTau181 plasma, pTau181/AB42 CSF and/or tTau/AB42 CSF
Test Order ID: 12345
https://www.examplelab.com/testpage (link to test page on your website)

 

pTau181 Notes

The Elecsys pTau181 plasma assay is intended to aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline in adult patients aged 55 years and older, presenting with signs, symptoms, or complaints of cognitive decline in a primary care setting. The performance of Elecsys Phospho-Tau (181P) Plasma has not been established for:

  • Predicting development of dementia or other neurologic conditions.
  • Monitoring responses to therapies.

 

CSF Notes

  • A positive pTau181/Abeta42 or tTau/Abeta42 ratio result in CSF does not establish a diagnosis of Alzheimer’s disease (AD) and should always be interpreted in conjunction with clinical information.

  • The performance of the test for African-American, Asian, and other races had high uncertainty due to the limited number of patients studied.

 

Reference

  1. Elecsys® Method Sheets: ms_08821941190, ms_08846693160, ms_08846685190, ms_09697870501